Eli Lilly and Novo Nordisk plan to announce new drug pricing deals with the White House, including for their weight loss medicines, in return for Medicare coverage of their products, Endpoints News reported on Tuesday.

Last week, Novo came over the top of an original Pfizer deal with Metsera with an up to $9bn offer for the biotech, sparking one of the most contentious bidding wars over a biotech in recent memory.